Boehringer Ingelheim (Canada) Ltd., launches ULTRA^™ Fel-O-Vax^®, the first and only ½ mL vaccine line for cats  

BURLINGTON, Ontario (January 19, 2015) – Boehringer Ingelheim (Canada) Ltd. (BICL), announces the launch of ULTRA^™ Fel-O-Vax^®, the first ½ mL vaccine line for cats. ULTRA^™ Fel-O-Vax^® joins its partner canine product line, ULTRA^™ Duramune^®, as the only pet vaccine lines on the market with 50% less volume per dose.

Built on the foundation of the Fel-O-Vax^® vaccine line, ULTRA^™ Fel-O-Vax^® features the same proven level of efficacy the industry has come to expect from Boehringer Ingelheim pet vaccines for 30 years. But now, using Purefil^™ Technology and half the volume, vaccination injections are now more comfortable and less stressful for both the veterinarian and the pet, helping to make return visits more likely than ever.

ULTRA^™ Fel-O-Vax^® was created with both patients and pet owners in mind. As a  ½ mL feline vaccine line, ULTRA^™ Fel-O-Vax^® allows less vaccine volume to be injected over the lifetime of the cat. Eighty-five percent of cat owners believe that reducing injection volume over the lifetime of their cats is important, according to a recent survey of pet owners.¹

The recent research also found that the vast majority (92 percent) of cat owners highly value a vaccine that incorporates the latest in purification technology and reduced injection volume.¹ ULTRA^™ Fel-O-Vax^® is manufactured with PureFil^™ Technology, which includes improved purification processes and tighter manufacturing profiles, resulting in more serial-to-serial consistency, reduced extraneous proteins and less cellular debris.

“ULTRA Fel-O-Vax offers veterinarians the opportunity to provide best medicine to their feline patients with less vaccine volume and the same uncompromising efficacy,” said Dr. Ed Doornenbal, Technical Services Veterinarian, BICL. “We believe this groundbreaking vaccine offers a more comfortable patient experience and leads to better owner compliance for next year’s visit.”

The ULTRA^™ Fel-O-Vax^® vaccine line is available in core and non-core combinations to more closely align with American Association of Feline Practitioners Feline Vaccination guidelines,² including BICL’s exclusive dual-strain calicivirus (FCV) for better cross-neutralization³ and near-perfect, proven feline leukemia (FeLV) protection.^4-9

About Boehringer Ingelheim (Canada) Ltd.
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Taking social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure corresponds to 19.5% of its net sales.

The Canadian headquarters of Boehringer Ingelheim was established in 1972 in Montreal, Quebec and is now located in Burlington, Ontario. Boehringer Ingelheim employs more than 550 people across Canada.

For more information please visit www.boehringer-ingelheim.ca